Cowen and Company reaffirmed their outperform rating on shares of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) in a research report sent to investors on Thursday. Cowen and Company currently has a $42.00 price target on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. Needham & Company LLC reiterated a buy rating and issued a $49.00 price objective on shares of Acadia Pharmaceuticals in a research report on Friday, August 5th. HC Wainwright reiterated a buy rating and issued a $60.00 price objective on shares of Acadia Pharmaceuticals in a research report on Monday, August 8th. Vetr downgraded Acadia Pharmaceuticals from a strong-buy rating to a buy rating and set a $41.00 price objective for the company. in a research report on Tuesday, July 26th. JMP Securities reissued a buy rating and set a $45.00 target price on shares of Acadia Pharmaceuticals in a research note on Wednesday, August 10th. Finally, Jefferies Group reissued a buy rating on shares of Acadia Pharmaceuticals in a research note on Wednesday, August 10th. Five investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of Buy and an average target price of $41.67.

Acadia Pharmaceuticals (NASDAQ:ACAD) opened at 29.06 on Thursday. The company has a 50 day moving average price of $26.48 and a 200-day moving average price of $32.00. The company’s market capitalization is $3.52 billion. Acadia Pharmaceuticals has a one year low of $16.64 and a one year high of $42.49.

Acadia Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.56) by $0.05. The firm earned $5.30 million during the quarter, compared to the consensus estimate of $2.90 million. Acadia Pharmaceuticals had a negative return on equity of 58.46% and a negative net margin of 4,427.79%. The business’s quarterly revenue was up 13489.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.39) EPS. Analysts expect that Acadia Pharmaceuticals will post ($2.34) EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company purchased a new position in Acadia Pharmaceuticals during the third quarter worth $111,000. Tower Research Capital LLC TRC increased its position in Acadia Pharmaceuticals by 1,529.8% in the second quarter. Tower Research Capital LLC TRC now owns 4,205 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 3,947 shares in the last quarter. Winslow Evans & Crocker Inc. increased its position in Acadia Pharmaceuticals by 120.0% in the second quarter. Winslow Evans & Crocker Inc. now owns 4,400 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 2,400 shares in the last quarter. BlackRock Inc. increased its position in Acadia Pharmaceuticals by 139.5% in the first quarter. BlackRock Inc. now owns 5,414 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 3,153 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC increased its position in Acadia Pharmaceuticals by 21.3% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 5,629 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 990 shares in the last quarter. 92.76% of the stock is currently owned by institutional investors.

Acadia Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).

5 Day Chart for NASDAQ:ACAD

Receive News & Stock Ratings for Acadia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.